Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-jRCTs071250059) titled 'Treatment protocol for adult acute lymphoblastic leukemia -ALL/MRD2025- (JSCT ALL/MRD2025)' on Aug. 7.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Koichi Akashi
Condition:
acute lymphoblastic leukemia
Intervention:
In CD19-positive non-Ph ALL, blinatumomab (Blina) will be used upfront to achieve and maintain MRD negativity. In CD19-negative non-Ph ALL, patients who remain MRD-positive after the second consolidation cycle will undergo allogeneic hematopoietic stem cell transplantation (allo-...